The Bottom Line

Basal cell carcinoma (BCC) is the most common skin cancer, but it comes in several different types that behave very differently. The most common type (nodular) is slow-growing and highly curable. The most aggressive type (morpheaform) hides under normal-looking skin and requires more intensive treatment. Knowing your BCC subtype helps your doctor choose the best treatment and helps you understand what to expect.

What Is Basal Cell Carcinoma?

Basal cell carcinoma (BCC) is a cancer that starts in the deepest layer of your outer skin. It is the most common cancer in humans and is almost always caused by long-term sun exposure. BCC almost never spreads to other organs, but it does grow into surrounding tissue and can cause serious damage if not treated. The good news is that when caught and treated, cure rates are very high.

What many people do not realize is that BCC is not just one disease—it comes in several distinct subtypes, each with its own appearance, behavior, and best treatment approach. A pathologist identifies the subtype by examining a sample of the tumor under a microscope.

The Main Types of Basal Cell Carcinoma

Nodular BCC — The Most Common Type

Nodular BCC accounts for 60–80% of all BCC cases. It typically appears as a shiny, pearly, or translucent bump on the skin, often with tiny red blood vessels (called telangiectasia) visible on its surface. In some cases, the center breaks down to form a small sore or crust, which dermatologists sometimes call a “rodent ulcer.”

Nodular BCC grows relatively slowly and invades into the skin layer beneath the surface. The tumor often extends further beneath the skin than it looks from the outside—in 30–50% of cases, the real edge of the tumor lies beyond what is visible. Recurrence rates after standard surgical removal are 5–10%, and most cases respond well to surgery or Mohs micrographic surgery.

Superficial BCC — The Most Treatable Type

Superficial BCC makes up about 15–35% of cases and looks quite different from the nodular type. It appears as a flat, red, scaly patch or plaque. It is often mistaken for eczema, psoriasis, or a persistent rash, which can delay diagnosis. Superficial BCC stays near the surface of the skin and does not grow deeply.

This is the most favorable type to have. Recurrence rates after surgery are only 3–5%. Even better, superficial BCC responds very well to non-surgical treatments: topical creams like 5-fluorouracil (5-FU) and imiquimod achieve cure rates of 85–95%. Photodynamic therapy (a light-based treatment) also works very well for this subtype.

Morpheaform (Sclerosing) BCC — The Most Aggressive Type

Morpheaform BCC is the most aggressive subtype, making up 5–10% of cases. It looks like a pale, flat, scar-like patch with indistinct edges—and that is exactly what makes it so tricky. Because it blends into normal skin and does not have obvious borders, it is easy to underestimate how large the tumor really is.

Under a microscope, the cancer cells of morpheaform BCC are scattered in thin strands through a dense, fibrous tissue rather than forming the neat nests seen in other types. This scattered growth pattern means the tumor spreads further beneath the surface than it appears. Perineural invasion—where cancer cells grow along nerve pathways—occurs in 10–25% of morpheaform cases, compared to about 5% in nodular BCC. This increases the risk of the cancer coming back.

With standard surgical excision, morpheaform BCC comes back 15–25% of the time. Mohs micrographic surgery—a specialized technique where the surgeon removes thin layers and checks margins during the procedure—reduces recurrence to less than 2%. Non-surgical treatments like topical creams, radiation, or cryotherapy are not appropriate for morpheaform BCC.

Basosquamous Carcinoma — A Rare but Aggressive Variant

Basosquamous carcinoma is a rare subtype (less than 1–3% of BCC cases) that has features of both basal cell and squamous cell carcinoma. It behaves more aggressively than standard BCC, with higher rates of perineural invasion (20–30%) and an increased risk of spreading to lymph nodes. Five-year survival rates are around 75–85%, lower than the 99% seen with conventional BCC. This type always requires Mohs surgery, and your doctor may also recommend radiation or other treatments.

Other Variants

Several less common BCC subtypes exist, including micronodular BCC (small, widely spaced nests that can invade deeply) and infundibulocystic BCC (which forms cyst-like structures and carries a good prognosis). Your pathology report will specify which type you have.

What Determines Your Treatment Plan?

Your dermatologist will recommend a treatment based on several factors:

  • Subtype: Superficial BCC may be treated with creams or light therapy; morpheaform always needs Mohs surgery
  • Location: Tumors on the face, especially around the eyes, nose, ears, or lips, are treated more carefully to preserve appearance and function
  • Size: Tumors larger than 2 cm are considered high-risk and usually need Mohs surgery
  • Perineural invasion: If cancer has grown along nerves, more aggressive surgery and possibly radiation are needed
  • Recurrence: A BCC that has come back after previous treatment almost always requires Mohs surgery
  • Immune status: People who are immunosuppressed (for example, organ transplant recipients) tend to develop more aggressive tumors

Treatment Options at a Glance

Standard surgical excision removes the tumor plus a rim of normal skin. Cure rates are excellent for nodular and superficial BCC (95%+) but lower for morpheaform. This is a straightforward outpatient procedure done under local anesthesia.

Mohs micrographic surgery removes the tumor one thin layer at a time, with each layer checked under the microscope immediately. This allows the surgeon to remove all cancer while sparing the maximum amount of healthy tissue. Cure rates exceed 99% for primary BCC. It is the preferred treatment for morpheaform, basosquamous, recurrent, or large BCCs.

Topical treatments (5-FU and imiquimod creams) are applied directly to the skin for weeks and are best suited for superficial BCC. They are not appropriate for deeper or more aggressive types.

Radiation therapy is an option for patients who cannot have surgery. It achieves good results (90–95% complete response for BCC) but is usually reserved for specific situations.

Hedgehog pathway inhibitors (vismodegib, sonidegib) are oral medications for locally advanced BCC that cannot be removed with surgery. They target a molecular pathway that drives BCC growth.

When to See a Dermatologist

  • You notice a shiny, pearly bump that does not go away or occasionally bleeds
  • You have a flat, scaly red patch that has been present for more than a few weeks
  • You have a pale, scar-like spot that you do not remember injuring
  • A previously treated BCC site looks changed or a new bump has developed nearby
  • You have a personal or family history of skin cancer and have not had a full skin exam recently

Frequently Asked Questions

What does it mean if my BCC is morpheaform?

Morpheaform BCC is the most aggressive subtype and has a higher chance of coming back (15–25%) after standard surgery compared with other types. Mohs micrographic surgery is strongly recommended because it can track and remove the hidden strands of cancer cells. This type also needs closer follow-up after treatment.

Can superficial BCC be treated with a cream instead of surgery?

Yes, in many cases. Topical 5-FU and imiquimod achieve cure rates of 85–95% for superficial BCC, especially for small, thin lesions. Surgery has slightly higher cure rates, but topical treatment avoids a scar and is a reasonable choice for selected patients. Your dermatologist will help you decide based on lesion size, location, and your overall health.

Is perineural invasion serious?

Yes. When BCC grows along nerve pathways, it can travel further from the main tumor and is more likely to come back. Perineural invasion usually means your doctor will recommend Mohs surgery with wider margins, and in some cases, radiation therapy after surgery to reduce recurrence risk.

What is my risk of BCC coming back after treatment?

It depends on the subtype and treatment method. Superficial BCC treated with excision or topical therapy: 3–5% recurrence. Nodular BCC with standard excision: 5–10%. Morpheaform with standard excision: 15–25%. Any BCC treated with Mohs surgery: less than 2%. Your dermatologist will recommend a follow-up schedule based on your specific risk.

References

  1. Sexton M, Huff C, Johnson M, et al. Comparison of histologic subtypes of basal cell carcinoma and frequency of clinically undetected subtypes. J Am Acad Dermatol. 2009;60(4):541-547.
  2. Robins P, Dzubow L, Rigel DS. Basal cell carcinoma. Dermatol Clin. 1983;1(2):267-281.
  3. Leibovitch I, Huilgol SC, Selva D, et al. Basal cell carcinoma treated with Mohs micrographic surgery in Australia: outcome analysis. J Am Acad Dermatol. 2005;53(3):445-451.
  4. Mohs FE. Micrographic surgery for basal cell epithelioma. Arch Dermatol. 1967;95(4):335-338.
  5. Foley P, Lansbury L, Thorne K, et al. Epidemiological trends in basal cell carcinoma. Australas J Dermatol. 2013;54(1):32-38.

Trusted Resources

Always consult a board-certified dermatologist for diagnosis and treatment of any skin cancer. This article is for educational purposes and does not replace individualized medical advice.